Stay updated on FGF401 in HCC and Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the FGF401 in HCC and Solid Tumors Clinical Trial page.

Latest updates to the FGF401 in HCC and Solid Tumors Clinical Trial page
- Check2 days agoChange DetectedUpdated page revision from v3.0.1 to v3.0.2, indicating a small update to content or features. The 'Back to Top' navigation element was removed.SummaryDifference0.1%
- Check9 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.1%
- Check16 days agoChange DetectedThe web page has undergone significant updates, including the addition of new facility names and locations across various countries, while also removing several previous location entries. Notably, the drug names 'roblitinib' and 'spartalizumab' have been retained, indicating a focus on specific treatments.SummaryDifference3%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check45 days agoChange DetectedThe page has been updated to version v2.16.10, and the previous service alert regarding planned maintenance has been removed.SummaryDifference0.7%
Stay in the know with updates to FGF401 in HCC and Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FGF401 in HCC and Solid Tumors Clinical Trial page.